{"commentary":{"count":29,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":18,"youtube":7,"podcast":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05361720\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT05361720","nct_id":"NCT05361720","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05361720. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"INDUCTION: Patients receive ipilimumab and nivolumab IV on day 1. Cycles repeat every 21 days for 4 cycles.\n\nMAINTENANCE: Patients receive nivolumab IV on day 1. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.","label":"Arm I (ipilimumab, nivolumab)","type":"EXPERIMENTAL"},{"description":"Patients receive nivolumab IV on day 1 and cabozantinib PO QD. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.","label":"Arm II (nivolumab, cabozantinib)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)","United States Department of Defense"],"completion_date":{"date":"2028-07-01","type":"ESTIMATED"},"conditions":["Advanced Clear Cell Renal Cell Carcinoma","Metastatic Clear Cell Renal Cell Carcinoma","Stage III Renal Cell Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8"],"enrollment":{"count":54,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Cabozantinib","type":"DRUG"},{"name":"Ipilimumab","type":"BIOLOGICAL"},{"name":"Nivolumab","type":"BIOLOGICAL"}],"last_update":"2026-08-19","lead_sponsor":"Vanderbilt-Ingram Cancer Center","official_title":"Optimal Treatment by Invoking Biologic Clusters in Renal Cell Carcinoma (OPTIC RCC)","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-10-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall response rate (ORR) (Arm 1)","timeFrame":"Up to 4 years"},{"measure":"Overall response rate (Arm 2)","timeFrame":"Up to 4 years"}],"references":[],"start_date":{"date":"2022-12-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study","url":"https://clinicaltrials.gov/study/NCT05361720"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05361720"}